Pyxis Oncology Q3 EPS Estimate Lowered by Leerink Partnrs

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities researchers at Leerink Partnrs cut their Q3 2024 EPS estimates for Pyxis Oncology in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their previous forecast of ($0.28). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.07) EPS.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04.

A number of other research analysts have also recently commented on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, August 16th. Finally, Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Pyxis Oncology presently has an average rating of “Buy” and a consensus target price of $9.00.

Pyxis Oncology Stock Down 2.1 %

Shares of Pyxis Oncology stock opened at $3.23 on Friday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The company has a market capitalization of $190.21 million, a PE ratio of -2.38 and a beta of 1.27. The stock’s fifty day moving average is $3.53 and its two-hundred day moving average is $3.79.

Institutional Trading of Pyxis Oncology

Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Pyxis Oncology during the 1st quarter worth $59,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Pyxis Oncology in the 1st quarter valued at about $351,000. Vanguard Group Inc. grew its position in shares of Pyxis Oncology by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after buying an additional 94,740 shares during the last quarter. StemPoint Capital LP bought a new position in shares of Pyxis Oncology during the 1st quarter worth approximately $7,643,000. Finally, Ikarian Capital LLC bought a new position in shares of Pyxis Oncology during the 1st quarter worth approximately $7,082,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.